Market News

Legal Perspective on Outset Medical, Inc. Securities Fraud Lawsuit – OM Investors Legal Perspective on Outset Medical, Inc. Securities Fraud Lawsuit – OM Investors

Legal Action Against Outset Medical, Inc.

Allegations of securities fraud have surfaced against Outset Medical, Inc. Investors holding substantial losses now have the unique opportunity to take the lead in a class action lawsuit.

Class Period and Plaintiff Deadline

The Class Period under scrutiny spans from August 1, 2022, to August 7, 2024, with the impending Lead Plaintiff Deadline set for October 28, 2024.

Missing Disclosures and Allegations

During the Class Period, Defendants purportedly neglected to disclose vital information to investors. This information includes the improper marketing of Tablo products for continuous renal replacement therapy, a FDA unapproved indication, among other missteps allegedly taken by Outset Medical.

Deficient Sales Team Allegations

An additional claim suggests that Outset Medical had issues with its sales team and processes, hindering the effective sales ramp of Tablo products. This, in turn, was projected to negatively impact revenue growth.

Path Ahead for Investors

Investors looking to be part of the class action need not take immediate action but can choose to engage legal counsel or remain as absent members. For more information and inquiries, contacting the counsel or visiting specified websites is recommended.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Information

For individuals seeking additional details about this class action lawsuit or wishing to discuss their rights or concerns, reaching out to the specified contacts via phone, email, or website is advised.

See also  Analysis of AMD Stock Before Q2 Earnings ReportThe Battle for AMD Stock: A Deep Dive Before Q2 Earnings Report

SOURCE Glancy Prongay & Murray LLP